HomeAI · summaries
Storia in 2 fonti
'Provocative' Survival Result in Myelofibrosis Trial
But phase III study testing selinexor plus ruxolitinib splits on its main goals
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
- ·
medpagetoday.com
'Provocative' Survival Result in Myelofibrosis Trial
But phase III study testing selinexor plus ruxolitinib splits on its main goals